Friday, 3 August 2012

BUKA BERSAMAN.. BREAKING THE RAMADAN FAST IN BOGOR, INDONESIA

Exactly 44 hours after leaving the Blue House among the Indians, I walked out of the customs hall at the Soekarno-Hatta International Airport at CGK in Jakarta..Visa on arrival, you pay them 25 dollars and they give you a stamp and the immigration official affixes the stamp on your passport and within a minute or so you are out of the immigration and customs hall.
The Flight was a Qatar Airways Flight from Doha to Jakarta, a nine hour flight, very similar to Miami to Paris. The breakfast had been exceptionally good, even by QR Qatar Airways standards..
My friends were waiting at the airport and very soon we were on our way to Bogor, Friday and it was around 430 pm and within one hour it is the time for Buka Bersaman, eating together, a metaphor for breaking the Ramadan Fast.
Jakarta is a very congested city and depending upon the time of the day, you can be in traffic for hours on end. We were not unlucky and within one hour and half we arrived at the Resto Gunung Mas, a family seafood restaurant in Sentul City which is in the outskirts of Bogor.
There were six of them, Javanese names do not give you a clue about their religious affiliation.. even though one has to assume that most people are moslem in this populous islamic country.
You know enough about Indonesian food, so what would you like? asked my friend, who is in charge of the Travel Agency here in Bogor.
A typical Indo meal was requested: fish, chicken, shrimp, green vegetables. Time passed quickly enough and i noticed that no one was gorging themselves but eating just enough to satisfy their apetite. 
We went upstairs to the offices of my friend, whom I had come to visit, the humble man of Bogor.
He has Nespresso coffee machine and it was nice to drink a familiar drink and it was time to repair to the hotel room to fall asleep.


I must say that there was not a single discussion about Religion or Ramadan but mainly the conversation was centered around the purpose of my visit to Bogor and Jakarta: Health and Happiness and Compassion towards others...

Tuesday, 17 July 2012

OBESITY AND SOCIAL STIGMA


Stigmatization of obese individuals by human resource professionals: an experimental study

Katrin E GielStephan ZipfelManuela AlizadehNorbert SchäffelerCarmen ZahnDaniel WesselFriedrich W HesseSyra Thiel and Ansgar Thiel
For all author emails, please log on.
BMC Public Health 2012, 12:525 doi:10.1186/1471-2458-12-525
Published: 16 July 2012

Abstract (provisional)

Background

Weight-related stigmatization is as a public health problem. It impairs the psychological well-being of obese individuals and hinders them from adopting weight-loss behaviors. We conducted an experimental study to investigate weight stigmatization in work settings using a sample of experienced human resource (HR) professionals from a real-life employment setting.

Methods

In a cross-sectional, computer-based experimental study, a volunteer sample of 127 HR professionals (age: 41.1 +/- 10.9 yrs., 56% female), who regularly make career decisions about other people, evaluated individuals shown in standardized photographs regarding work-related prestige and achievements. The photographed individuals differed with respect to gender, ethnicity, and Body Mass Index (BMI).

Results

Participants underestimated the occupational prestige of obese individuals and overestimated it for normal-weight individuals. Obese people were more often disqualified from being hired and less often nominated for a supervisory position, while non-ethnic normal-weight individuals were favored. Stigmatization was most pronounced in obese females.

Conclusions

The data suggest that HR professionals are prone to pronounced weight stigmatization, especially in women. This highlights the need for interventions targeting this stigmatization as well as stigma-management strategies for obese individuals. Weight stigmatization and its consequences needs to be a topic that is more strongly addressed in clinical obesity care.

Monday, 2 July 2012

AVANDIA, WELBUTRIN,PAXIL AND THE DRUG COMPANY GSK


GlaxoSmithKline to pay $3bn in US drug fraud scandal
    
Diabetes medication Avandia is one of the three drugs concerned in the fraud case
GlaxoSmithKline (GSK) is to pay $3bn (£1.9bn) in the largest healthcare fraud settlement in US history.

The drug giant is to plead guilty to promoting two drugs for unapproved uses and failing to report safety data about a diabetes drug to the Food and Drug Administration (FDA).
The settlement will cover criminal fines as well as civil settlements with the federal and state governments.
The case concerns the drugs Paxil, Wellbutrin and Avandia.
Deputy US Attorney General James Cole told a news conference in Washington DC that the settlement was "unprecedented in both size and scope".
Doctors bribed
GSK, one of the world's largest healthcare and pharmaceuticals companies, admitted to promoting antidepressants Paxil and Wellbutrin for unapproved uses, including treatment of children and adolescents.
The illegal practice is known as off-label marketing.
The company also conceded charges that it held back data and made unsupported safety claims over its diabetes drug Avandia.
In addition, GSK has been found guilty of paying kickbacks to doctors.
"The sales force bribed physicians to prescribe GSK products using every imaginable form of high-priced entertainment, from Hawaiian vacations [and] paying doctors millions of dollars to go on speaking tours, to tickets to Madonna concerts," said US attorney Carmin Ortiz.
As part of the settlement, GSK agreed to be monitored by government officials for five years.
GSK said in a statement it would pay the fines through existing cash resources.
Andrew Witty, the firm's chief executive, said procedures for compliance, marketing and selling had been changed at GSK's US unit.
"We have learnt from the mistakes that were made," Mr Witty said. "When necessary, we have removed employees who have engaged in misconduct."

Sunday, 17 June 2012

PANCREATIC REST FOR NEWLY DIAGNOSED TYPE 2 DIABETES


Early and intensive therapy preserved beta-cell function long term in type 2 diabetes


  • June 13, 2012
AllPHILADELPHIA — Initiating intensive therapy in treatment-naïve, newly-diagnosed patients with type 2 diabetes preserved beta-cell function for 3.5 years, according to data presented at the American Diabetes Association’s 72nd Scientific Sessions.
“Everybody knows that type 2 diabetes is a progressive disease and this progression is determined by a progressive decline in beta-cell function over time,” Ildiko Lingvay, MD, assistant professor of internal medicine at University of Texas Southwestern Medical Center, said during her presentation. “Our ideal goal as physicians when we treat our patients is to preserve beta-cell function, either by decreasing the slope of decline or, ideally, by stabilizing beta-cell function over time — a disease-modifying effect.”
In light of data from the UKPDS and ADOPT studies, Lingvay and colleagues developed a treatment strategy that they hoped would preserve beta-cell function in treatment-naïve patients who were newly diagnosed with type 2 diabetes. They randomly assigned patients to insulin-based treatment or triple oral therapy preceded by a short, 3-month course of insulin-based therapy.
patients were treated with insulin and metformin during the 3-month run-in, after which they were randomly assigned to treatment continuation or triple oral therapy. The goal of the run-in period, according to Lingvay was to remove the transient stunning of beta-cell function due to glucotoxicity.
All patients were treated with Novolog 70/30 at 0.2 U/kg or metformin at 500 mg daily, which was titrated weekly to 1,000 mg twice daily. Triple oral therapy included glyburide 1.25 mg twice daily, which was titrated throughout the study; metformin 1,000 mg twice daily and pioglitazone (Actos, Takeda) 15 mg titrated during 3 months to 45 mg.
Treatment failure was defined as HbA1c ≥8%. If patients in the triple oral arm achieved this target, they were switched to the insulin group. Similarly, if patients in the insulin group achieved this target, they remained on insulin with the option to change the frequency or type of treatment.
Lingvay and colleagues screened 67 patients; 63 enrolled and 58 finished the 3-month run-in and were randomized in a 1:1 fashion with continued insulin or were switched to triple oral therapy.
At the time of diagnosis, the average HbA1c was 10.6%; after the 3 months of the run-in period, HbA1c was reduced to 5.9% and 100% of participants achieved the ADA-recommended goal of HbA1c ≤7%.
At the time of randomization, age was about 45 years, 80% were minorities, average BMI was 36 and the insulin dose was 0.6 U/kg, which was three times the initial dose patients.
There was a rapid improvement in glycemic control within the first 3 months, with normalization of glucose then sustained glycemic control through 3.5 years, regardless of treatment assignment. 
Treatment failure occurred in three patients in the insulin group and five in the triple oral therapy group.
In regards to the main outcome of beta-cell function, C-peptide AUC/glucose AUC did not show the expected decline, Lingvay said. Stabilization of beta-cell function occurred in both treatment groups.
Weight increased in both groups, but there was no statistically significant difference. Mild hypoglycemia was defined conservatively (any home glucose measurement of <70 mg/dl associated with any symptoms suggestive of hypoglycemia) and occurred at a rate of one per month during the first 4 months. According to Lingvay, the rate decreased to less than 0.5 events per month and remained low during the course of the study.
“This is a very important finding, in light of a very low HbA1c achieved and maintained throughout the study; and the fact that; all patients were treated with insulin or sulfonylurea.”
Lingvay said follow-up continues and 6-year results will be available soon.
Before concluding, however, she shared some lessons learned while conducting this study.
“I suggest we try to achieve glycemic normalization as quickly as possible after diagnosis. Additionally, I recommend we maintain glycemic control long-term. Because diabetes is such a multifactorial disease with so many underlying pathophysiological components, I don’t personally think monotherapy is the answer to change the course of the disease. I recommend combination treatment with complimentary mechanisms of action. Also, [we should] anticipate disease progression. Treatment intensification should be done while the patient’s glycemic control is still within the target range; I would not recommend waiting until HbA1c go above target before intensifying treatment.” – by Stacey L. Fisher
For more information:
Disclosure: Dr. Lingvay serves on medical advisory board for NovoNordisk, and the study was sponsored through and investigator-initiated trial grant from NovoNordisk.

Saturday, 12 May 2012

Run for your life! Study finds joggers live an average of six years longer


Need a solid excuse to dust off your running shoes? Joggers have been found to live an average of six years longer than those who don't jog.
However, you’ll have to run for at least one hour a week for benefit, according to a new study in Denmark.
Researchers found that jogging was associated with a 44 per cent reduction in the relative risk of death for those over 35 years compared with deaths among those who did not run.
The same benefit applied to both men and women.
The 44 per cent reduction translates to an ‘age-adjusted survival benefit’ of 6.2 years in men and 5.6 years in women, according to Dr. Peter Schnohr, chief cardiologist from the Copenhagen City Heart study.
Furthermore, the jogger’s lives are not only longer but happier too as those who ran reported an overall sense of well-being, said Schnohr. 



'The results of our research allow us to definitively answer the question of whether jogging is good for your health,' Schnohr said in a statement.
'We can say with certainty that regular jogging increases longevity. The good news is that you don't actually need to do that much to reap the benefits,' he continued. 


Fighting fit: The study also found that joggers led happier lives
The study also found that the optimum benefit of jogging was for those who jogged at a slow-to-average pace for between an hour and two and a half hours spread over two or three weekly sessions.
The revelations are the latest to come out of the Copenhagen City Heart Study which began in 1976. At the beginning of the programme the study’s 19,329 participants’ age ranged from 20 to 79.
The 1,878 participants in the most recent study were asked how often and how quickly they ran.
Researchers then compared deaths among the joggers among the non-joggers in the main study pool of almost 20,000.
Over 35 years, 122 joggers died compared with 10,158 non-joggers.

Thursday, 5 April 2012

DIABETES CARE WITHOUT BORDERS


Dear Friends:
The Endocrine Society is objecting the fact that some of the anti diabetic medications would be sold over the counter, insisting that the diabetes care has to be under SUPERVISION of a medical doctor who would coordinate the other activities. Ever since I have begun working with the Indians, I have known that model to be faulty, the only way we can improve the health of the Indians, is work together, not in a hierarchical fashion but in a circular fashion and make the patient feel and understand that it is possible to take care of their health. I have always joked to Michele, My aim is to make my self Unemployed! Indian Health Services and the Tribal Programmes are leading the way and showing the light on how to better look after an indian patient with Diabetes: cooperation and consensus. I am becoming more and more an ornament, I happily admit!
Best wishes
I am enlosing a letter I wrote to Maurits Van Pelt who runs a diabetes are programme in Cambodia (mopotsyo.org) in which people from the community are taught to take care of people with diabetes , the so called Peer to Peer Education Programme. I know you have thousands of emails to read, but read my letter to him if you have a minute to spare.
Dear Maurits,
Recently I heard a comment, I am not sure where in Asia, that the doctor said: I am against medications being freely made available to the patient. Current studies show that up to 80 per cent of the patients (abstract presented at ADA last year) do not follow the regimen prescribed. Among my own patients I can be sure that they take the morning dosage and often do not take the afternoon dosage because of their social life balanced towards evenings and nights.
FDA in the USA, not always a user friendly organization seems to have decided to make available without prescription commonly used drugs. But Endocrine Society vehemently protests that Diabetes medications be excluded from this benevolence.
Just look at the tone of the letter from Endo Society, a little bit condescending and arrogant. We in the field recognize that the days of Doctor directed or supervised Diabetes Care is going to be history and that innovation is coming in from empowerment is given to the patient and not provide more authority to the Doctor.
My role in the team in our clinic, is to see the patient last, rather than first and organize their therapeutic regimen, but after they have been seen by: optometrist, podiatrist, diabetes nutritionist and diabetes educator, I am given time to counsel and talk about spiritual matters (this being possible among the Native American Indians). The Diabetes Educators would have already begun the change in treatment regimen if they thought so, I agree with them almost always. I do keep an eye on prevention factors on complications,especially nephropathy, again following very local criteria, such as
our patients normal BP is around 110-120/60-70.
There is unexplained haematuria with or without diabetes, possibility of IgA nephropathy.
Protein is always measured in the urine and followed. (this is also being automated without my participation) and i check that.
So the time given to me, which is about 45 min to 1 hour per patient: 25 % on medically related matters and 75% on non medical non pharmaceutical matters.
Our patients have easy access to medications and strips to measure blood sugars.
So our system is much closer to MOPOTSYO model than the model espoused by Endocrine society and here is their note:
Society Recommends Exclusion of Diabetes Medications from Nonprescription Drug Expansion

Endocrine Insider
April 4, 2012

To increase patients’ access to safe treatments for certain conditions, the U.S. Food and Drug Administration (FDA) is considering making some commonly used prescription drugs available without a prescription. FDA held a hearing on March 22-23 to receive public feedback on the expansion, which is proposed to provide more ready access for medications for highly prevalent diseases that can be self-diagnosed and treated. As examples of such diseases, FDA listed hyperlipidemia, hypertension, migraine headaches, and asthma in a February 28 request for comments. The Society is concerned that FDA might also include medications for diabetes under this expansion due to the high prevalence of the disease.

As a result of its concerns, the Society submitted a comment letterurging the FDA to exclude diabetes medications from this expansion due to the complexity of treating and managing diabetes. The Society recommends that diabetes medications continue to be prescribed by a physician and that allied health professionals should continue to provide education and assistance to patients in coordination with a supervising physician. The FDA is currently considering comments on the proposed expansion and the Society will inform its members once a determination has been made. Additional information can be accessed here.



as an anthropologist I have to question the motive of the society, which is primarily to protect the endocrinologists rather than the welfare of the patient? Medications are freely available in most parts of the world and in many countries patients never get to see a doctor but a pharmacist is the one that gives the advice.



Quantitatively speaking, the results of National Studies in the USA, does not show that the measurements are any better than poor, developing countries of the world. and of course if you compare, the results among the Mexican Americans in Texas or Blacks in Georgia or American Indians in South Dakota, most of the developing countries have similar or better quantitative profiles . In Basra, Iraq a war zone the average A1C is very similar to the above groups mentioned.



What Endocrine Society need to understand is that Diabetes as we see it (excluding type 1) is a social disease and the answers are going to be social in nature, with a good contribution from medications. In a study published in the last couple of days they wanted to show that injectable Exanetide was better than Metformin, but it turned out to be not superior to any of the medications we commonly use except Sitagliptin, another newer medication.



Today I will start reading about Outcome Measurements and also i was happy to see that the World Diabetes Foundation has taken an interest in the Diabetes among Indigenous peoples of the world! I will be in touch with you regarding how to approach them.



Enjoy your holidays. You deserve it. It is a beautiful day in Paris. I will be leaving for the Indians (Nebraska and South Dakota) on April 16th.



Yehuda